Wirkstoff(e)

• (S)-3-(1-(9H-Purin-6-ylamino)Ethyl)-8-Chlor-2-Phenylisochinolin-1(2H)-on
• 1-[4-bromo-5-[1-ethyl-7-(methylamino)-2-oxo-1,2-dihydro-1,6-naphthyridin-3-yl]-2-fluorophenyl]-3-phenylurea
• 17-(allylamino)-17-demethoxygeldanamycin, hydroquinone, hydrochloride
• 68Ga-DOTA-pABzA-DIG-dPhe-Gln-Trp-Ala-Val-Gly-His-NHCHCH2-CHCH322
• A live attenuated bioengineered Listeria monocytogenes cancer immunotherapy
• Alisertib
• Anagrelid
• Belinostat
• Bezuclastinib
• Darinaparsin
• Fenretinide
• Gegen humanes CD30-Antigen gerichteter, kovalent an die zytotoxische Substanz Monomethylauristatin E gebundener monoklonaler Antikörper
• Ilixadencel
• Imatinib mesilate
• Inhibitor of primary and secondary KIT and PDGFR alpha kinase mutants found in GIST
• Ligand binding moiety to STAT3, a chemical linker, and a ligand binding moiety to an E3 ligase that leads to STAT3 degradation
• Mogamulizumab
• N-(2-aminophenyl)-4-(1-[(1,3-dimethyl-1H-pyrazol-4-yl)methyl]piperidin)benzamide
• N-(methyl-diazacyclohexyl-methylbenzamide)-azaphenyl-aminothiopyrrole
• Nanatinostat, valganciclovir
• Nilotinib
• Olverembatinib
• Ponatinib
• Pralatrexat
• Recombinant anti-CD3-bi-single-chain-Fv-diphtheria toxin fusion protein
• Regorafenib
• Retifanlimab
• Romidepsin
• Small Molecule Inhibitor of Exon 17 mutant KIT
• Small-molecule oral KIT inhibitor targeting activating mutations and resistance mutations
• Sunitinib
• Yttrium (90Y) Edotreotid
• Zanolimumab
• [4-(Methyl-1H-pyrazol-4-yl)-benzyl] -(6-[7-(3-pyrrolidin-1-yl-propoxy)-imidazo[1,2-a] pyridin-3-yl]-pyrimidin-4-yl]-amine

Handelsname(n)

• ADCETRIS
• Ayvakit
• BELEODAQ
• GLEEVEC
• GLIVEC
• IMATINIB TEVA B.V.
• ISTODAX
• Imatinib Koanaa
• QINLOCK
• STIVARGA
• SUTENT
• Sunitinib Accord
• Thiotepa Riemser